Modulators of the Glutamatergic System: Implications for the Development of Improved Therapeutics in Mood Disorders
The DOI matches its Crossref record.
Abstract
Mood disorders have traditionally been conceptualized as neurochemical disorders, but there is now evidence from a variety of sources demonstrating regional reductions in central nervous system volume as well as reductions in the numbers and/or sizes of glia and neurons in discrete brain areas. Although the precise cellular mechanisms underlying these morphometric changes remain to be fully elucidated, the data suggest that severe mood disorders are associated with impairments of structural plasticity and cellular resilience. One neurotransmitter system implicated in regulating neuronal plasticity and cellular resilience in a variety of neuropsychiatric disorders is the glutamatergic system. Recent preclinical studies have shown that the glutamatergic system often represents indirect targets for the actions of antidepressants and mood stabilizers. For many refractory patients, new drugs that simply mimic traditional drugs, which directly or indirectly alter monoamine levels, may be of limited benefit. This article reviews the growing body of data suggesting that agents which modulate the glutamatergic system may have utility in the long-term treatment of severe, recurrent mood disorders. Such strategies may serve to enhance and maintain normal synaptic connectivity, thereby allowing the chemical signal to reinstate the optimal functioning of critical circuits necessary for normal affective functioning. There are a number of glutamatergic “plasticity-enhancing” strategies that may be of considerable utility in the treatment of mood disorders. Among the most immediate are N-methyl-D-aspartate antagonists, glutamate release–reducing agents, and α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid potentiators. This research progress holds much promise for the development of novel therapeutics for the treatment of severe, refractory mood disorders. Psychopharmacology Bulletin. 2002;36(4):35-83
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Self-citationTargeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Self-citationMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Manji, H. K., Quiroz, J. A., Sporn, J., Payne, J. L., Denicoff, K., A. Gray, N., Zarate, C. A., & Charney, D. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00117-3 · Cited by 505
Self-citation
Metadata
- Authors
- Zarate, C. A., MD, Quiroz, J., MD, Payne, J., MD, Manji, A. H. K., & MD
- Venue
- Psychopharmacology Bulletin
- Publisher
- MedWorks Media
- Published
- 2025-08-12
- Volume
- 36
- Issue
- 4
- Pages
- 35-83
- ISSN
- 0048-5764 (ISSN-L)
- 2472-2448
- OpenAlex
- W27315567
- Cited by
- 104
- References
- 0
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulators of the Glutamatergic System: Implications for the Development of Improved Therapeutics in Mood Disorders. https://app.cochat.ai/papers/10.64719/pb.4204
- The paper
- Zarate, C. A., MD, Quiroz, J., MD, Payne, J., MD, Manji, A. H. K., & MD. (2025). Modulators of the Glutamatergic System: Implications for the Development of Improved Therapeutics in Mood Disorders. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.4204
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.